There is a critical need for a tool that enables the detection of key neurodegenerative disease biomarkers from plasma samples to enhance analysis of patient material within clinical trials. A high-performance absolute quantification solution is urgently required to ensure precise, reliable, and reproducible results across and within longitudinal studies.
Target 48 Neurodegeneration
Join our neurology spotlight series and get updated information on coming soon Target 48 Neurodegeneration Panel
Coming soon – Target 48 Neurodegeneration panel
Overview
Proteins*
42 1 Panel
Samples
40 per Kit
Sample volume
1 µL per panel
Readout
pg/mL Absolute units
Runs on
Signature Q100
*anticipated in the final product
Ready to take the next step?
Contact us to discover more and preorder your kit.
Absolute quantification
Compare across cohorts, time points, and studies, empowered by precise absolute quantification. Generate rich, robust data from just a few microlitres of plasma or CSF, maximizing the value of each precious sample.
Key markers
Quantify pTau217, Aβ40, Aβ42, NfL, GFAP, and more in a single, scalable assay—saving time, cost, and precious patient sample.
Profound insights
Uncover disease-driving biology with biomarker content purposefully curated by global experts and biobank data, spanning synaptic proteins, neuroinflammation, clearance, and beyond.
Elevate your immunoassay experience
Beyond the Olink panel lies a wide range of free tools for study design, statistical analysis, data visualization and quality control. There’s also continuous support from our data science experts and customer service teams. We’re proud to be active partners to thousands of researchers, from small lab teams to major institutions and consortia.